Shionogi receives FDA nod for first oral COVID-19 post-exposure prevention pill

Shionogi announced that the U.S. Food and Drug Administration has granted approval for its oral antiviral designed to prevent COVID-19 after exposure.

The product is indicated for adults and children aged 12 and older who have been in close contact with a confirmed case, offering a pill-based alternative to existing injectable or inhaled options.

This marks the first FDA-approved oral medication specifically for post-exposure prophylaxis against COVID-19, expanding the toolkit for managing outbreaks.

Shionogi highlighted that the approval could open new market opportunities in the United States and complement its existing portfolio of antiviral therapies.